New Colon Cancer Biomarkers May Guide Development of Personalized Treatment

Researchers are first to demonstrate the role of a circular RNA, ciRS-7, in colon cancer

Researchers at Baylor Scott & White Research Institute identified a new genetic biomarker for colon cancer that may lead to development of more targeted treatment of the disease. The study, which appeared in a recent issue of Clinical Cancer Research, was the first to demonstrate the role of a novel class of RNA, circular RNA ciRS-7, in colon cancer.

Circular RNAs, a recently discovered type of non-coding RNA, are gene regulators emerging as a key player in the development of cancer in several studies. For this study, researchers evaluated the expression levels of ciRS-7 in patients with colon cancer and healthy subjects to explore its clinical significance in the disease.

Findings showed an increased presence of ciRS-7 in colon cancer patient tissues. High levels of ciRS-7 promoted rapid cancer cell growth and appeared to be a predictor for poor survival in patients with colon cancer.

The results suggest ciRS-7 may one day help predict patient prognosis and guide treatment decisions for colon cancer, the third most commonly diagnosed cancer and the second leading cause of cancer death in men and women combined in the U.S.

"This study is important for the way we treat colon cancer, because ciRS-7 controls the expression of many genes," said Ajay Goel, Ph.D., director of gastrointestinal research and translational genomics and oncology at Baylor Scott & White Research Institute and co-author of the study. "Since cancer therapies aimed at targeting a single gene have not been very effective, targeting a circular RNA such as ciRS-7 might be a more promising and attractive option as it regulates the expression of several cancer causing genes. Identifying key treatment targets helps with the development of very specific, personalized anti-cancer interventions that may save more lives in the future."


# # #

About Baylor Scott & White Health
As the largest not-for-profit health system in the state of Texas, Baylor Scott & White promotes the health and well-being of every individual, family and community it serves. It is committed to making quality care more accessible, convenient and affordable through its integrated delivery network, which includes the Baylor Scott & White Health Plan, Baylor Scott & White Research Institute, the Baylor Scott & White Quality Alliance and its leading digital health platform – MyBSWHealth. Through 51 hospitals and more than 1,200 access points, including flagship academic medical centers in Dallas, Fort Worth and Temple, the system offers the full continuum of care, from primary to award-winning specialty care. Founded as a Christian ministry of healing more than a century ago, Baylor Scott & White today serves more than three million Texans. For more information, visit: BSWHealth.com